Ninlaro Looking Positive In MM Maintenance On Back Of TOURMALINE Data

Takeda's Ninlaro seems to have proved its mettle in the first major placebo-controlled trial assessing a proteasome inhibitor as a single-agent maintenance therapy in multiple myeloma.